Apolipoprotein C1 Test

Apolipoprotein C1, often called ApoC1, is the smallest of the apolipoproteins, which are the family of proteins that help move fats, such as cholesterol and triglycerides, through the bloodstream. It is mainly made in the liver but also produced by immune cells called macrophages and in tissues like the brain, kidneys, and lungs. ApoC1 attaches to fat-carrying particles in the blood, including high-density lipoprotein (HDL) and very-low-density lipoprotein (VLDL, a triglyceride-rich lipoprotein). It can move between these particles depending on your body’s metabolic state, which allows it to fine-tune how fats are handled.

In lipid metabolism, ApoC1 acts as both a regulator and a gatekeeper. It can block triglyceride-rich lipoproteins such as VLDL from binding to receptors on the liver, slowing their clearance from the bloodstream. It also reduces the activity of an enzyme called lipoprotein lipase, which normally breaks down triglycerides. Together, these actions can raise blood triglyceride levels. On the other hand, ApoC1 also inhibits cholesteryl ester transfer protein (CETP), an enzyme that moves cholesterol between lipoproteins. By doing so, ApoC1 may increase protective HDL cholesterol and, in some cases, reduce the risk of artery-clogging plaque. This makes its role in heart disease complex: in some settings it may contribute to atherosclerosis, while in others it may protect against it.

Beyond fat metabolism, ApoC1 plays roles in immunity and inflammation. It can influence how immune cells respond during infections and chronic diseases such as diabetes. In certain cancers, including brain tumors (glioblastoma) and kidney cancer, ApoC1 has been shown to promote tumor growth and spread. It does this by altering the behavior of macrophages, the immune cells that can either attack tumors or, when reprogrammed, help them survive. ApoC1 also makes cancer cells more resistant to ferroptosis, a type of cell death triggered by iron and lipid damage.

Because of these wide-ranging effects, ApoC1 is more than just a lipid regulator. It is increasingly studied as both a biomarker that can signal risk for cardiovascular or metabolic disease and as a potential therapeutic target in cancer and immune disorders.